Physician profile
Jeffrey Jenson
NPI 1740211390
$1,131.13
in general payments reported to CMS, 2019-2025
18 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.84 · 2022: $12.96 · 2023: $226 · 2024: $502 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $261.96 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $256.64 | 2023-2025 | Wegovy |
| Neurocrine Biosciences, INC. | $78.13 | 2024-2025 | Ingrezza |
| Lilly USA, LLC | $71.44 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Medtronic, INC. | $62.84 | 2021 | |
| Kerecis Limited | $57.56 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Novartis Pharmaceuticals Corporation | $57.55 | 2023-2024 | |
| Pfizer INC. | $43.90 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $42.46 | 2023 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.34 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.37 | 2023-2024 | Xifaxan |
| Exact Sciences Corporation | $29.99 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.60 | 2025 | Caplyta |
| Astellas Pharma US INC | $19.27 | 2024 | Veozah |
| Tactile Systems Technology INC | $15.50 | 2023 | Flexitouch Plus, Entre Plus |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $14.93 | 2023 | Puraply |
| Esperion Therapeutics, INC. | $14.69 | 2024 | Nexletol |
| Abbvie INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.